Stemline Therapeutics,Inc. (NASDAQ:STML) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

Stemline Therapeutics,Inc. (NASDAQ:STML) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.Submission of Matters to a Vote of Security Holders.

The 2018 annual meeting of stockholders of Stemline Therapeutics,Inc. (“Stemline”) was held on June21, 2018. The following matters were voted on by the stockholders: (i)the election of five directors; (ii)the ratification of the appointment of Ernst& Young LLP as Stemline’s independent registered public accounting firm for the year ending December31, 2018; and (iii)the approval of an amendment to Stemline’s 2016 Equity Incentive Plan to increase the number of authorized shares issuable by 2,900,000 shares.

Item 1: Election of directors:

Nominee

TotalVotesFor

TotalVotes Withheld

BrokerNon-Votes

Ivan Bergstein

19,928,914

631,444

4,882,449

Alan Forman

18,264,343

2,296,015

4,882,449

Mark Sard

20,545,384

14,974

4,882,449

Darren Cline

20,545,284

15,074

4,882,449

Daniel Hume

20,545,345

15,013

4,882,449

Item 2: Ratification of the appointment of Ernst& Young LLP as Stemline’s independent registered public accounting firm for the year ending December31, 2018:

TotalVotesFor

TotalVotesAgainst

Abstention

BrokerNon-Votes

25,430,520

7,508

4,779

Item 3: Vote to approve an amendment to Stemline’s 2016 Equity Incentive Plan to increase the number of authorized shares issuable by 2,900,000 shares:

TotalVotesFor

TotalVotesAgainst

Abstention

BrokerNon-Votes

13,039,687

7,498,535

22,136

4,882,449


About Stemline Therapeutics,Inc. (NASDAQ:STML)

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.